Clinical Trials
6 trialsNCT04666038 2026-04-24
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03575351 2025-08-03
TRANSFORM
Celgene
Phase 3 Completed
NCT01996865 2025-07-10
MAGNIFY
Celgene
Phase 3 Completed
NCT03483103 2023-12-20
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Juno Therapeutics, a Subsidiary of Celgene
Phase 2 Completed
NCT01938001 2023-02-22
AUGMENT
Celgene
Phase 3 Completed
NCT01777152 2021-11-30
ECHELON-2
Seagen Inc.
Phase 3 Completed